<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Newsroom

Press Releases

Our latest announcements

Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

Journal of Thoracic Oncology Study: VerStrat provides oncologists with more information to personalize therapy for their patients.

VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

Analysis showed that the VeriStrat test was able to identify patients more likely to have a slower progression of disease with select treatments.

Biodesix Closes Series D Financing

Biodesix has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for VeriStrat.

Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Biodesix Appoints Vice President of Clinical Development & Medical Affairs

Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.

Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.

Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.

VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.